Radiotherapy and chemotherapy for gliomas

Current Opinion in Oncology

Volumn 8, Issue 3, 1996, Pages 196-203

  Delattre, Jean Yves ^a   Uchuya, Miguel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; 4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMONAFIDE; BROXURIDINE; CAMPTOTHECIN; CARBOGEN; CARBOPLATIN; CARMUSTINE; DIAZIQUONE; FLUOROURACIL; FOLIC ACID; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MINOCYCLINE; MITOLACTOL; NICOTINAMIDE; NITROSOUREA DERIVATIVE; PACLITAXEL; PIRITREXIM; PREDNISONE; PROCARBAZINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; THIOTEPA; TIOGUANINE; VINCRISTINE;

CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; GLIOMA; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW;

EID: 0029975607     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199605000-00005     Document Type: Review

References (76)

1. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y: Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Int J Radiat Oncol Biol Phys 1994, 30:1179-1185.
2. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glatstein E: National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1994, 30:583-590.
3. Prados MD, Wara MW, Edwards MSB, Larson DA, Lamborn K, Levin VA: The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 1995, 32:85-91. Seventy-eight patients with a brainstem or thalamic glioma received 7800 cGy of hyperfractionated radiation therapy. The median survival time was 12.7 months. Increasing the dose from 72 to 78 Gy did not improve survival.
4. Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB, Selch MT, Cherlow JM, Finlay JL, Wara MW: Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. Cancer 1994, 74:1827-1834. Sixty-six children with brainstem gliomas were treated with 7800 cGy of hyperfractionated radiotherapy. Overall survival was 35% at 1 year, indicating no benefit in comparison with lower doses of hyperfractionated radiotherapy.
5. Bernstein M, Laperriere N, Glen J, Leung P, Thomason C, Landon AE: Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 1994, 30:1213-1217.
6. Fernandez PM, Zamorano L, Yakar D, Gaspar L, Warmelink C: Permanent iodine-125 implants in the up-front treatment of malignant gliomas. Neurosurgery 1995, 36:467-473.
7. Green SB, Shapiro WR, Burger PC, Selker RG, VanGilder JC, Saris S, Malkin MG, Mealey J Jr, Neal J, Robertson JT, Olson J: A randomized trial of interstitial radiotherapy (RT) boost for newly diagnosed malignant glioma: Brain Tumor Cooperative Group (BTCG) trial 8701 [abstract]. Proc Am Soc Clin Oncol 1994, 13:174. This phase III study showed that an interstitial radiotherapy boost for newly diagnosed malignant gliomas increased median survival time.
8. Schupak K, Malkin M, Anderson L, Arbit E, Lindsley K, Leibel S: The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys 1995, 32:1167-1176.
9. Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A, Cassady JR: Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis. Int J Radiat Oncol Biol Phys 1994, 30:591-600. This phase II study suggests that an interstitial thermoradiotherapy boost increases survival when compared with interstitial brachytherapy alone.
10. Hall WA, Djalilian HR, Sperduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 1995, 13:1642-1648. Thirty-five patients with recurrent malignant gliomas were treated with stereotactic radiosurgery. The actuarial survival time from radiosurgery was 8 months.
11. 125I brachytherapy, but tumor volume and median follow-up were disparate between the groups.
12. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995, 82:530-535.
13. Buatti JM, Friedman WA, Bova FJ, Mendenhall WM: Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int J Radiat Oncol Biol Phys 1995, 32:205-210.
14. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB, Alexander III E, Friedman WA, Kinsella TJ: Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1995, 32:931-941. One hundred fifteen patients with malignant gliomas received external radiotherapy and linac-based radiosurgery. Median survival time was 21 months for glioblastoma multiforme, whereas anaplastic astrocytoma patients had a 2-year survival of 72%. In comparison with previous RTOG series, treatment with radiosurgery appeared superior, but most patients from RTOG series had larger tumors.
15. Mehta MP: Glioblastoma multiforme: "Who should receive stereotactic boost therapy?" Int J Radiat Oncol Biol Phys 1994, 30:746.
16. Dunbar SF, Tarbell NJ, Kooy HM, Alexander E III, Black PM, Barnes PD, Goumnerova L, Scott RM, Pomeroy SL, La Vally B, Sallan SE, Loeffler JS: Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys 1994, 30:531-539.
17. Shibamoto Y, Yamashita J, Takahashi M, Abe M: Intraoperative radiation therapy for brain tumors with emphasis on retreatment for recurrence following full-dose external beam irradiation. Am J Clin Oncol 1994, 17:396-399.
18. Fujiwara T, Honma Y, Ogawa T, Irie K, Kuyama H, Nagao S, Takashima H, Hosokawa A, Ohkawa M, Tanabe M: Intraoperative radiotherapy for gliomas. J Neurooncol 1995, 23:81-86.
19. Greenberg HS, Chandler WF, Ensminger WD, Sandler H, Junck L, Page MA, Crane O, McKeever P, Tankanow R, Bromberg J: Radiosensitization with carotid intra-arterial bromodeoxyuridine t 5-fluorouracil biomodulation for malignant gliomas. Neurology 1994, 44:1715-1720.
20. Levin VA, Prados MR, Wara WM, Davis RL, Gutin PH, Phillips TL, Lamborn K, Wilson CB: Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995, 32:75-83. One hundred sixteen patients with anaplastic astrocytomas received conventional radiotherapy (60 Gy) and continuous intravenous infusion of bromodeoxyuridine followed by chemotherapy with procarbazine, lomustine, and vincristine. Estimated 4-year survival was 46%. A long median survival time (63 months) was found in the 87 patients treated with limited-field irradiation.
21. Cartei F, Danesi R, Ducci F, Fatigante L, Caciagli PG, Del Tacca M, Laddaga M: Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. Acta Oncol 1994, 33:969-973.
22. Fatigante L, Cartei F, Ducci F, Marini C, Prediletto R, Caciagli P, Laddaga M: Carbogen breathing in patients with glioblastoma multiforme submitted to radiotherapy: assessment of gas exchange parameters. Acta Oncol 1994, 33:807-811.
23. Stragliotto G, Fankhauser H: Biodistribution of boron sulfhydryl (BSH) neutron capture therapy in patients with intracranial tumors. Neurosurgery 1995, 36:285-293. The uptake of boron sulfhydryl after intravenous administration was analyzed in neoplastic and normal tissues in 61 patients with intracranial tumors. Tumor boron concentrations were the highest in patients with high-grade gliomas. Boron concentrations in normal brain were extremely low. Tumor-blood boron ratios above 1 found in most high-grade tumors 18 hours after an injection of boron sulfhydryl.
24. 11SH in patients with glioblastoma. Cancer Res 1994, 54:6318-6320.
25. 11SH. J Neurosurg 1994, 81:741-744.
26. Ceberg CP, Persson A, Brun A, Huiskamp R, Fyhr A-S, Persson BRR, Salford LG: Performance of sulfhydryl boron hydride in patients with grade III and IV astrocytoma: a basis for boron neutron capture therapy. J Neurosurg 1995, 83:79-85
27. Kreth FW, Faist M, Warnke PC, Robner R, Volk B, Ostertag ChB: Interstitial radiosurgery of low-grade gliomas. J Neurosurg 1995, 82:418-429.
28. Lunsford LD, Somaza S, Kondziolka D, Flickinger JC: Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 1995, 82:523-529.
29. Pu AT, Sandler HM, Radany EH, Blaivas M, Page MA, Greenberg HS, Junck L, Ross DA: Low grade gliomas: preliminary analysis of failure patterns among patients treated using 30 conformal external beam irradiation. Int J Radiat Oncol Biol Phys 1995, 31:461-466.
30. Scott CB, Nelson JS, Farnan NC, Curran WJ, Murray KJ, Fischbach AJ, Gaspar LE, Nelson DF: Central pathology review in clinical trials for patients with malignant glioma. Cancer 1995, 76:307-313. This examination of a central versus an institutional pathology review demonstrates a low level of agreement of anaplastic astrocytoma classification and a high level of agreement on glioblastoma multiforme classification. If institutional reports had been accepted, a 59% underestimation in the median survival of anaplastic astrocytoma patients would have been made in comparison with centrally defined anaplastic astrocytoma.
31. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L: Age influences chemotherapy response in astrocytomas. Neurology 1995, 45:929-933. This study of 148 patients with malignant gliomas showed that response to nitrosoureas was strongly influenced by age. The response rate was six- to sevenfold higher in patients aged less than 40 years in comparison with patients aged 60 years or more. The results remained significant after adjustment for tumor grade.
32. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M: Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 1994, 30A:1809-1815.
33. 18F-fluoro-2-deoxyglucose. Posttreatment hypermetabolism was significantly correlated with survival.
34. Malkin MG, Green SB, Byar DP, Strike TA, Burger PC, Vogel FS, Pistenmaa DA, Mahaley MS Jr, Ransohoff J, Shapiro WR, Mealey J Jr, Robertson JT, Selker RG, Van Gilder JC: Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the brain tumor study group. J Neurooncol 1994, 22:55-65. A randomized trial comparing the activity of PCNU and AZQ in 152 patients with de novo or recurrent gliomas. Median survival times were 11 months for the PCNU group and 8.4 months for the AZQ group (P = 0.01), indicating superiority of PCNU.
35. Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR, Bertolone SJ, McGuire P, Cherlow JM, Tefft M, Turski PA, Wara WM, Edwards M, Sutton LN, Berger MS, Epstein F, Ayers G, Allen JC, Packer PJ: Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine and prednisone with the eight-drugs-in-1-day-regimen. J Clin Oncol 1995, 13:112-123. There is no benefit for the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with lomustine, vincristine, and prednisone.
36. Finlay JL, Geyer JR, Turski PA, Yates AJ, Boyett JM, Allen JC, Packer RJ: Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the "8-drugs-in-1-day" regimen. J Neurooncol 1994, 21:255-265.
37. Heimans JJ, Vermoken JB, Wolbers JG, Eeltink CM, Meijer OWM, Taphoorn MJB, Beijnen JH: Paclitaxel (Taxol®) concentrations in brain tumor tissue. Ann Oncol 1994, 5:951-953.
38. Chamberlain MC, Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 1995, 13:2066-2071.
39. Bleehen NM, Newman HVF, Rampling RP, Ramsay JR, Roberts JT, Bedford P, Nethersell ABW: A phase II study of oral piritrexim in recurrent high-grade (III,IV) glioma. Br J Cancer 1995, 72:766-768.
40. Levitt R, Buckner JC, Cascino TL, Burch PA, Morton RF, Westberg MW, Goldberg RM, Gallagher JG, O'Fallon JR, Scheithauer BW: Phase II study of amonafide in patients with recurrent glioma. J Neurooncol 1995, 23:87-93.
41. Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME: A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 1995, 75:2762-2767.
42. Friedman HS, Dolan ME, Pegg AE, Marcelli S, Keir S, Catino JJ, Bigner DD, Schold SC Jr: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995, 55:2853-2857.
43. Chamberlain MC, Grafe MR: Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995, 13:2072-2076. Fourteen children with recurrent chiasmatic-hypothalamic gliomas received oral etoposide. Most had failed a first-line nitrosourea-based chemotherapy. Five patients had an objective response and three had stable disease. The median duration of response was 8 months. Tolerance was acceptable.
44. Stewart DJ, Dahrouge S, Soltys K: A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J Neurooncol 1995, 23:249-252.
45. Buckner JC, Brown LD, Kugler JW, Cascino TL, Krook JE, Mailliard JA, Kardinal CG, Tschetter LK, O'Fallon JR, Scheithauer BW: Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995, 82:430-435. The use of carmustine plus interferon alfa is safe and active in recurrent gliomas, but the contribution of interferon to the antitumor activity cannot be assessed from this trial.
46. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS: Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994, 35:378-388. A careful study of factors that affect response to chemotherapy. This multidrug chemotherapy regimen does not seem superior to single-agent therapy.
47. Ameri A, Sanson M, Monjour A, Ronchin P, Poisson M, Delattre JY: Treatment of recurrent supratentorial gliomas with the association of ifosfamide, carboplatin and etoposide: a phase II study [abstract]. Neurology 1995, 45(suppl 4):A263.
48. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC, for the Polymer-Brain Tumor Treatment Group: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995, 345:1008-1012. A placebo-controlled trial showing that interstitial chemotherapy with polymers impregnated with carmustine is a safe and effective treatment for recurrent malignant gliomas. Median survival time was 7.2 months in patients treated with carmustine versus 5.3 months in patients who received placebos (P = 0.0006).
49. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H: Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rate intracranial 9L gliosarcoma model. Int J Cancer 1995, 62:605-609.
50. Weingart JO, Sipons EP, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995, 82:635-640.
51. Judy KD, Olivi A, Buahin KG, Domb A, Epstein JI, Colvin OM, Brem H: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 1995, 82:841-846.
52. Larner JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA: A phase 1-2 trial of superselective carboplatin, low-dose infusional 5-fluorouracil and concurrent radiation for high-grade gliomas. Am J Clin Oncol 1995, 18:1-7.
53. Kurpad S, Friedman HS, Archer GE, McLendon RE, Petros WM, Fuchs HE, Guaspari A, Bigner DD: Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. Cancer Res 1995, 55:3803-3809.
54. Newton HB, Newton CL: Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. J Neurooncol 1995, 24:285-292.
55. Jereb B, Petric-Grabnar G, Klun B, Lamovec J, Škrbec M, Šoos E: Addition of IFN-α to treatment of malignant brain tumors. Acta Oncol 1994, 33:651-654.
56. Boiardi A, Silvani A, Ruffini PA, Rivottini L, Parmiani G, Broggi G, Salmaggi A: Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-Lak) in recurrent glioblastoma patients. Cancer Immunol Immunother 1994, 39:193-197.
57. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995, 76:840-852. Reoperation and intracavitary lymphokine-activated killer cells and interleukin-2 increased survival in comparison with reoperation and chemotherapy in patients with recurrent glioblastoma multiforme. According to the authors, a prospective randomized trial is warranted.
58. 2: a preliminary report J Neurooncol 1995, 24:109-122.
59. Rich JN, Elion GB, Wellner D, Colvin OM, Groothuis DR, Hilton JH, Schlageter KE, Bigner DD, Griffith OW, Friedman HS: The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. Cancer Chemother Pharmacol 1995, 36:379-384.
60. Devineni D, Klein-Szanto A, Gallo JM: Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J Neurooncol 1995, 24:143-152
61. Inamura T, Nomura T, Bartus RT, Black KL: Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994, 81:752-758.
62. Baltuch GH, Dooley NP, Rostworowski KM, Villemure J-G, Yong VW: Protein kinase C isoform α overexpression in C6 glioma cells and its role in cell proliferation. J Neurooncol 1995, 24:241-250.
63. Ahmad S, Mineta T, Martuza RL, Glazer RI: Antisense expression of protein kinase C α inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 1994, 35:904-909.
64. Couldwell WT, Golpalakrishna R, Hinton DR, He S, Weiss MH, Law RE, Apuzzo MLJ: Hypericin: a potential antiglioma therapy. Neurosurgery 1994, 35:705-710.
65. Matsumoto T, Tani E, Yamaura I, Katsuya M, Kaba K: Effects of protein kinase C modulators on multidrug resistance in human glioma cells. Neurosurgery 1995, 36:565-572.
66. Meixensberger J, Herting B, Roggendorf W, Reichmann H: Metabolic patterns in malignant gliomas. J Neurooncol 1995, 24:153-161.
67. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 1995, 62:216-222.
68. 6-alkylguanidine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21:135-140.
69. 6-methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 1995, 61:321-326.
70. 6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 1995, 75:1339-1342.
71. Abe T, Hasegawa S, Taniguchi K, Yokomizo A, Kuwano T, Ono M, Mori T, Hori S, Kohno K, Kuwano M: Possible involvement of multidrug-resistance-associated protein (MRP) gene expression in spontaneous drug resistance to vincristine, etoposide and Adriamycin in human glioma cells. Int J Cancer 1994, 58:860-864.
72. Kondo S, Yin D, Morimura T, Takeuchi J: Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells. J Neurosurg 1995, 82:469-474.
73. Bergenheim AT, Björk P, Bergh J, von Schoultz E, Svedberg H, Henriksson R: Estramustine-binding protein and specific binding of the anti-mitotic compound estramustine in astrocytoma. Cancer Res 1994, 54:4974-4979.
74. Valbo C, Bergenheim T, Bergh A, Grankvist K, Henriksson R: DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain, suggesting an apoptotic cell death. Br J Cancer 1995, 71:717-720.
75. Bergenheim AT, Zackrisson B, Elfverson J, Roos G, Henrikson R: Radiosensitizing effect of estramustine in malignant glioma in vitro and in vivo. J Neurooncol 1995, 23:191-200.
76. Viola JJ, Agbaria R, Walbridge S, Oshiro EM, Johns DG, Kelley JA, Oldfield EH, Ram Z: In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 1995, 55:1306-1309.